Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Investing.com - TD Cowen raised its price target on BridgeBio Pharma (NASDAQ:BBIO) to $95.00 from $60.00 on Thursday, while maintaining its Buy rating on the stock. This new target matches the highest analyst price objective for BBIO, which is currently trading at $63.29 after posting impressive returns of 180% over the past year. According to InvestingPro data, the stock appears overvalued compared to its Fair Value estimate.
The significant price target increase follows Attruby’s quarterly sales growth of 51% quarter-over-quarter, which exceeded market expectations. According to TD Cowen, this growth was primarily driven by treatment-naive patients and accelerating new patient prescriptions. This aligns with InvestingPro data showing BridgeBio’s overall revenue growth of 7.62% over the last twelve months, with analysts anticipating continued sales growth this year.
The firm noted that BridgeBio has successfully transformed into a diversified orphan drug company, with positive clinical readouts in both limb-girdle muscular dystrophy (LGMD) and autosomal dominant hypocalcemia type 1 (ADH1) this week. Despite this positive momentum, which has contributed to the stock’s 23.81% surge in the past week, InvestingPro analysis indicates BBIO is not yet profitable, with a negative EBITDA of $623.73 million.
TD Cowen expressed confidence in BridgeBio’s upcoming achondroplasia trial, expected to report results in early 2026, predicting another successful outcome for the company’s late-stage pipeline.
The new price target is based on TD Cowen’s discounted cash flow (DCF) analysis, reflecting increased confidence in BridgeBio’s commercial execution and pipeline potential.
In other recent news, BridgeBio Pharma reported its third-quarter 2025 earnings, revealing a larger-than-expected loss with an EPS of -$0.95, compared to the forecasted -$0.88. However, the company’s revenue surpassed expectations, reaching $120.7 million against the anticipated $107.62 million. The strong performance was driven by U.S. Attruby sales, which totaled $108.1 million, exceeding Goldman Sachs’ estimates by 11% and consensus estimates by 6%.
Goldman Sachs responded by raising its price target for BridgeBio to $100, maintaining a Buy rating due to the robust sales figures. Similarly, Leerink Partners increased its price target to $75 from $68, keeping an Outperform rating, noting that BridgeBio’s sales were slightly ahead of their estimate and consensus. The company recorded 5,259 unique prescriptions from 1,355 unique prescribers, indicating strong market engagement. These developments reflect positive analyst sentiment and an optimistic outlook for BridgeBio’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.